Inceptor Bio and the University of Minnesota aim to build a novel iPSC platform to accelerate cell therapy drug development.
On June 30, 2022, Inceptor Bio, a US-based biotechnology company specializing in cell therapies for difficult-to-treat cancers, announced a collaboration with the University of Minnesota. Under the collaboration, the two parties plan to build a novel induced pluripotent stem cells (iPSC) platform to accelerate Inceptor Bio’s next-generation cell therapies platforms.
Inceptor Bio will receive an exclusive license to the technology developed under this collaboration. The company plans to advance multiple cell therapy products into clinical studies by incorporating the iPSC platform into its proprietary K62 platform for chimeric antigen receptor macrophage (CAR-M) therapy. CAR-M therapy increases the phagocytic capabilities of macrophages and supports a macrophage 1 (M1) anti-tumor phenotype as well as its novel co-stimulatory domain, M83, for CAR-natural killer cell therapies.
"iPSC-derived cell therapies have the potential to enable the next frontier of cell therapies. We are excited to work with [Beau] Webber at University of Minnesota and his team to develop this unique platform," said Mike Nicholson, president and chief operating officer, Inceptor Bio, in a company press release.
"The team at University of Minnesota is confident that Inceptor Bio is the right partner for building a differentiated iPSC platform to advance novel cell therapies," said Beau Webber, assistant professor in the Department of Pediatrics, Division of Hematology and Oncology, University of Minnesota, in the press release. "We are deeply encouraged by Inceptor Bio’s progress in the cell therapy arena, and we look forward to being part of future developments to help cure difficult-to-treat cancers."
Source: Inceptor Bio
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.